Athira Pharma (NASDAQ:LONA) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Athira Pharma (NASDAQ:LONA) in a report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock.

Several other equities analysts also recently weighed in on the company. Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Thursday, February 19th. Weiss Ratings assumed coverage on shares of Athira Pharma in a research note on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Finally, Wall Street Zen upgraded shares of Athira Pharma to a “hold” rating in a research note on Saturday, February 14th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.00.

Athira Pharma Price Performance

LONA opened at $5.63 on Thursday. The stock has a market capitalization of $22.18 million, a PE ratio of -0.58 and a beta of 2.72. Athira Pharma has a twelve month low of $2.20 and a twelve month high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.